Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.

Oncotarget - 29 Mar 2016

Zhang Lisa, Boufraqech Myriem, Lake Ross, Kebebew Electron

Abstract excerpt

Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, with no effective treatment currently available. Previously, we identified agents active against ATC cells, both in vitro and in vivo, using quantitative high-throughput screening of 3282 clinically approved drugs and small molecules. Here, we report that combining two of these active agents, carfilzomib, a second-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase Inhibitor p21
Share to Drug Synergism
Share to G2 Phase Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Deacetylase Inhibitors

Share to Hydroxamic Acids

Share to Oligopeptides

Share to Poly(ADP-ribose) Polymerases

Share to Thyroid Carcinoma, Anaplastic

Source

Open in PubMed Open full text

Identifiers

PMID: 26934320
DOI: 10.18632/oncotarget.7760
PMCID: PMC4941332

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.PMID 26934320Read ↗

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.Semantic proximity Read ↗

Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid CancerSemantic proximity Read ↗

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read ↗

Dual targeting of PDPK1 and BRAF V600E is synthetically lethalSemantic proximity Read ↗

Evaluating new treatments for anaplastic thyroid cancer.Semantic proximity Read ↗

The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.Semantic proximity Read ↗

HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid CancerSemantic proximity Read ↗

Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancerSemantic proximity Read ↗

A New Aurora in Anaplastic Thyroid Cancer TherapySemantic proximity Read ↗

Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.Semantic proximity Read ↗

Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody.Semantic proximity Read ↗

Combination therapy with BRAF and MEK inhibitors for anaplastic thyroid cancer: A report of two cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.